MCID: SPR009
MIFTS: 47

Sporadic Breast Cancer malady

Categories: Genetic diseases, Cancer diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Sporadic Breast Cancer

About this section

Aliases & Descriptions for Sporadic Breast Cancer:

Name: Sporadic Breast Cancer 11 13
 
Sporadic Breast Carcinoma 68

Classifications:



External Ids:

Disease Ontology11 DOID:8029
NCIt45 C7566

Summaries for Sporadic Breast Cancer

About this section
MalaCards based summary: Sporadic Breast Cancer, also known as sporadic breast carcinoma, is related to familial breast cancer and breast cancer. An important gene associated with Sporadic Breast Cancer is TTC4 (Tetratricopeptide Repeat Domain 4), and among its related pathways are PLK3 signaling events and Fanconi anemia pathway. Affiliated tissues include breast and endothelial, and related mouse phenotypes are Decreased viability after ionizing radiation and Decreased viability with cisplatin.

Related Diseases for Sporadic Breast Cancer

About this section

Diseases in the Breast Cancer family:

Breast Benign Neoplasm Inflammatory Breast Carcinoma
sporadic breast cancer Breast Carcinoma in Situ
Familial Breast Cancer Bard1-Related Susceptibility to Breast Cancer
Brip1-Related Breast Cancer Chek2-Related Susceptibility to Breast Cancer
Rad51-Related Susceptibility to Breast Cancer

Diseases related to Sporadic Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 145)
idRelated DiseaseScoreTop Affiliating Genes
1familial breast cancer29.9BRCA1, BRCA2, CHEK2
2breast cancer26.4ATM, BARD1, BRCA1, BRCA2, CHEK2, EMSY
3congenital pulmonary veins atresia or stenosis10.8BRCA1, BRCA2
4bronchopulmonary dysplasia10.7BRCA1, BRCA2
5vulvar angiokeratoma10.7ESR1, PGR
6central nervous system organ benign neoplasm10.6ESR1, PGR
7fallopian tube benign neoplasm10.6ESR1, PGR
8appendix leiomyoma10.6ESR1, PGR
9mixed cell adenoma10.6ESR1, PGR
10mixed cell type kidney wilms' tumor10.6PGR, TP53
11lethal congenital contracture syndrome 710.6BRCA1, BRCA2
12eyelid disease10.6ERBB2, ESR1
13autoimmune disease of blood10.6BRCA1, BRCA2, PGR
14selective ige deficiency disease10.6BRCA1, BRCA2, PGR
15papillary adenofibroma10.6BRCA1, BRCA2, TP53
16cystinosis, nephropathic10.5ERBB2, TP53
17cutaneous lupus erythematosus10.5BRCA1, BRCA2, ERBB2
18breast squamous cell carcinoma10.5BRCA1, BRCA2, PGR
19mediastinal neurilemmoma10.5BRCA1, BRCA2, PGR
20ossifying fibromyxoid tumor10.5ERBB2, PGR
21uterine body mixed cancer10.5ESR1, PGR, TP53
22perinatal intestinal perforation10.5ESR1, PGR
23cutaneous mucoepidermoid carcinoma10.5ERBB2, PGR
24bile duct disease10.5ATM, BRCA1, TP53
25ovarian cancer, somatic10.5BRCA1, BRCA2, ERBB2
26deafness, autosomal dominant 8/1210.5ESR1, ESR2, PGR
27epithelioid type angiomyolipoma10.5ESR1, PGR, TP53
28retroperitoneum carcinoma10.5ESR1, ESR2, PGR
29allergic cutaneous vasculitis10.5ESR1, ESR2, PGR
30gelatinous ascites10.5ERBB2, ESR1, PGR
31her2-receptor negative breast cancer10.4ERBB2, PGR
32simple partial epilepsy10.4PGR, TP53
33liddle syndrome, scnn1g-related10.4CHEK2, TP53
34glottis verrucous carcinoma10.4ERBB2, ESR1, PGR
35bartholin's gland adenoid cystic carcinoma10.4ESR1, PGR
36fallopian tube adenosarcoma10.4ESR1, PGR, TP53
37bladder colonic type adenocarcinoma10.4ERBB2, ESR1, PGR
38adenocarcinoma in situ10.4ERBB2, ESR1, PGR
39extragonadal nonseminomatous germ cell tumor10.4ERBB2, ESR1
40novak syndrome10.4ERBB2, ESR1, TP53
41animal phobia10.4ERBB2, PGR, TP53
42anomalous left coronary artery from the pulmonary artery10.4ERBB2, ESR1, PGR
43papillary carcinoma10.4ESR2, PGR, TP53
44fallopian tube mucinous adenocarcinoma10.4ERBB2, ESR1, TP53
45lateral sclerosis10.4ESR1, ESR2, PGR
46pleomorphic carcinoma10.4ERBB2, ESR1, PGR
47papillary thymic adenocarcinoma10.4ERBB2, ESR1, PGR
48breast malignant phyllodes tumor10.4ERBB2, ESR1, ESR2
49progesterone-receptor negative breast cancer10.4ERBB2, ESR1, PGR
50fallopian tube germ cell cancer10.4BRCA1, BRCA2, ESR1, PGR

Graphical network of the top 20 diseases related to Sporadic Breast Cancer:



Diseases related to sporadic breast cancer

Symptoms & Phenotypes for Sporadic Breast Cancer

About this section

GenomeRNAi Phenotypes related to Sporadic Breast Cancer according to GeneCards Suite gene sharing:

26
idDescriptionGenomeRNAi Source AccessionScoreTop Affiliating Genes
1GR00232-A-210.5ATM, BRCA1, BRCA2
2GR00101-A-410.0BARD1, BRCA1, BRCA2, RAD51
3GR00101-A-110.0BARD1, BRCA1, BRCA2, RAD51
4GR00103-A-09.2BRCA1, PGR, PTEN, RAD51, TP53, TTC4
5GR00151-A-28.2BARD1, BRCA1, BRCA2, RAD51, ATM, BARD1
6GR00250-A-38.1ATM, BARD1, BRCA1, BRCA2, CHEK2, RAD51
7GR00250-A-15.2ATM, BARD1, BRCA1, BRCA2, CHEK2, PTEN

MGI Mouse Phenotypes related to Sporadic Breast Cancer according to GeneCards Suite gene sharing:

41 (show all 17)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053698.3BRCA1, ERBB2, ESR1, ESR2, PGR, PTEN
2MP:00053758.2ATM, BRCA1, ESR1, ESR2, PTEN, TP53
3MP:00053718.1BRCA1, BRCA2, ERBB2, ESR1, ESR2, PGR
4MP:00053908.0BRCA1, BRCA2, ERBB2, ESR1, ESR2, PGR
5MP:00053797.8ATM, BRCA1, BRCA2, ERBB2, ESR1, ESR2
6MP:00053897.8ATM, BRCA1, BRCA2, ERBB2, ESR1, ESR2
7MP:00107717.7ATM, BRCA1, BRCA2, ERBB2, ESR1, ESR2
8MP:00053817.7BRCA1, BRCA2, ERBB2, ESR1, ESR2, PTEN
9MP:00053807.5ATM, BARD1, BRCA1, BRCA2, ERBB2, ESR1
10MP:00053867.1ATM, BRCA1, BRCA2, ERBB2, ESR1, ESR2
11MP:00028737.0BARD1, BRCA1, BRCA2, ERBB2, ESR1, ESR2
12MP:00036316.8ATM, BARD1, BRCA1, BRCA2, ERBB2, ESR1
13MP:00020066.5ATM, BARD1, BRCA1, BRCA2, CHEK2, ERBB2
14MP:00053786.5ATM, BARD1, BRCA1, BRCA2, ERBB2, ESR1
15MP:00053766.5ATM, BRCA1, BRCA2, CHEK2, ERBB2, ESR1
16MP:00053846.2ATM, BARD1, BRCA1, BRCA2, CHEK2, ERBB2
17MP:00107686.0ATM, BARD1, BRCA1, BRCA2, CHEK2, ERBB2

Drugs & Therapeutics for Sporadic Breast Cancer

About this section

Drugs for Sporadic Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 22)
idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Paclitaxelapproved, vet_approvedPhase 2275833069-62-436314
Synonyms:
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
157069-30-2
33069-62-4
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.
7,11-Methano-5H-cyclodeca[3,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.
7-Epi-Paclitaxel
7-Epi-Taxol
7-Epipaclitaxel
7-Epitaxol
7-epi-Paclitaxel
7-epi-Taxol
AB00513812
ABI 007
ABI-007
ABI007
AC-675
AC1L1IOG
AC1L1VJI
AC1L9AVF
ACon1_002231
ANX-513
Abraxane
Abraxane (TN)
Abraxane I.V. Suspension
Abraxis BioScience brand of albumin-bound paclitaxel
Ambotz33069-62-4
Anzatax
Asotax
BIDD:PXR0046
BMS 181339-01
BMS-181339
BMS-181339-01
BPBio1_000320
BRD-A23723433-001-01-2
BRD-A28746609-001-04-0
BRD-K62008436-001-03-1
BSPBio_000290
BSPBio_001152
BSPBio_002614
Bio-0076
Bio1_000362
Bio1_000851
Bio1_001340
Bio2_000416
Bio2_000896
Bristaxol
C07394
C466458
C47H51NO14
CCRIS 8143
CHEBI:103439
CHEBI:45863
CHEMBL100910
CHEMBL418410
CHEMBL48
CID36314
CID441276
CID4666
CID6713921
CID6915727
CPD-8718
Capxol
D00491
DB01229
DHP-107
DHP-208
DRG-0190
DTS-301
DivK1c_000441
EU-0101201
Ebetaxel
EmPAC
Epitaxol
Genaxol
Genetaxyl
Genexol
Genexol-PM
HMS1362J13
HMS1568O12
HMS1792J13
HMS1922K08
HMS1990J13
HMS2090D07
HMS2093K15
HMS501G03
HSDB 6839
I06-0014
IDI1_000441
IDI1_002171
Intaxel
KBio1_000441
KBio2_000492
KBio2_002016
KBio2_002509
KBio2_003060
KBio2_004584
KBio2_005077
KBio2_005628
KBio2_007152
KBio2_007645
KBio3_000903
KBio3_000904
KBio3_001834
KBio3_002987
KBioGR_000492
KBioGR_001893
 
KBioGR_002509
KBioSS_000492
KBioSS_002016
KBioSS_002517
LMPR0104390001
LS-31070
LipoPac
Lopac0_001201
MBT 0206
MEGxp0_001940
MLS000863266
MLS001077297
MLS002154218
MLS002172439
MLS002695976
MPI-5018
Micellar Paclitaxel
Mitotax
MolPort-001-742-627
MolPort-003-665-783
MolPort-003-932-365
NCGC00024995-02
NCGC00024995-03
NCGC00024995-04
NCGC00024995-05
NCGC00024995-06
NCGC00024995-07
NCGC00164367-01
NCGC00164367-02
NCGC00164367-03
NCI60_000601
NINDS_000441
NK 105
NP-010981
NSC 125973
NSC-125973
NSC125973
NSC358882
Nanotaxel
Neuro_000060
Nova-12005
OAS-PAC-100
OncoGel
Onxal
Onxol
Onxol, Taxol, Nov-Onxol, Paclitaxel
P1632
Paclical
Pacligel
Paclitaxel
Paclitaxel (JAN/USP)
Paclitaxel (JAN/USP/INN)
Paclitaxel (Taxol)
Paclitaxel [USAN:INN:BAN]
Paxceed
Paxene
Paxoral
Plaxicel
Praxel
Prestwick0_000155
Prestwick1_000155
Prestwick2_000155
Prestwick3_000155
Probes2_000350
QW 8184
S-8184 Paclitaxel Injectable Emulsion
S1150_Selleck
SDCCGMLS-0066823.P001
SDP-013
SMP1_000228
SMR000394086
SMR000857385
SPBio_000943
SPBio_002229
SPECTRUM1503908
ST50306996
Spectrum2_000872
Spectrum3_001057
Spectrum4_001197
Spectrum5_001491
Spectrum_001536
T 7402
T1912_SIGMA
T7191_SIGMA
T7402_SIGMA
TA1
TAXOL (TN)
TAXOL, 10-EPI,
TXL
TaxAlbin
Taxol
Taxol A
Taxol Konzentrat
Taxol.RTM. (Registered Trademark)
UNII-P88XT4IS4D
UPCMLD-DP108:001
UPCMLD-DP108:002
Vascular Wrap
Xorane
Yewtaxan
abi-007
albumin-bound paclitaxel
cMAP_000068
nab-paclitaxel
nchembio.188-comp1
nchembio.2007.34-comp9
nchembio.215-comp9
nchembio853-comp6
paclitaxel
weekly paclitaxel
2
Pregabalinapproved, illicit, investigationalPhase 2355148553-50-85486971
Synonyms:
(3S)-3-(aminomethyl)-5-methylhexanoic acid
(R-)-3-isobutyl GABA
(S)-3-(Aminomethyl)-5-methylhexanoic acid
(S)-3-Isobutyl gaba
(S+)-3-isobutyl GABA
121GE001
148553-50-8
3-Isobutyl gaba
3-isobutyl GABA
AC-1158
AC1NUP03
AKOS005145504
C080245
C8H17NO2
CHEBI:236161
CHEMBL1059
CI 1008
CI-1008
CID5486971
 
D02716
DB00230
FT-0080911
HSDB 7530
LS-75191
Lyrica
Lyrica (TN)
MolPort-000-861-733
PD 144723
PD-144723
Pregabalin
Pregabalin (JAN/USAN/INN)
Pregabalin [USAN]
Pregablin
S-(+)-3-isobutylgaba
S1731_Selleck
SBB062901
TL8001062
TOS-BB-0910
UNII-55JG375S6M
3Central Nervous System DepressantsPhase 212806
4Tranquilizing AgentsPhase 24164
5Albumin-Bound PaclitaxelPhase 22757
6Calcium, DietaryPhase 25525
7Psychotropic DrugsPhase 26279
8Peripheral Nervous System AgentsPhase 222776
9AnalgesicsPhase 211287
10calcium channel blockersPhase 21940
11Anti-Anxiety AgentsPhase 21816
12AnticonvulsantsPhase 22620
13Antineoplastic Agents, PhytogenicPhase 25420
14Antimitotic AgentsPhase 25498
15
OlaparibapprovedPhase 1126763113-22-023725625
Synonyms:
4-(3-{[4-(cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorobenzyl)phthalazin-1(2H)-one
4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one
4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
763113-22-0
937799-91-2
AKOS005145764
AZD 2281
AZD-2281
AZD2281
 
Acylpiperazine analogue, 47
CHEMBL521686
EC-000.2324
EN002690
FT-0083489
KU-0059436
KU-59436
Olaparib
Olaparib, KU-0059436, AZD2281, KU0059436, AZD2281
S1060_Selleck
olaparib
16
CarboplatinapprovedPhase 1198041575-94-410339178, 498142, 38904
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
Carbopaltin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Cbdca
Cyclobutane-1,1-dicarboxylate
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
EINECS 255-446-0
EU-0100230
Ercar
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
IUPAC: Azane
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
 
JM 8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
LS-117689
Lopac-C-2538
Lopac0_000230
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
NINDS_000892
NSC 201345
NSC 241240
NSC-241240
NSC201345
NSC241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
Platinum(II), (1, 1-cyclobutanedicar
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Platinum, {diammine[1,1-cyclobut
S1215_Selleck
SPBio_000716
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
Spectrum_001529
UNII-BG3F62OND5
azanide
carboplatin
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
cyclobutane-1,1-dicarboxylic acid
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
platinum(2+)
17Poly(ADP-ribose) Polymerase InhibitorsPhase 1309
18
Lapatinibapproved, investigational, Approved March 2007Early Phase 1296231277-92-2, 388082-78-8208908, 9941095
Synonyms:
1xkk
231277-92-2
388082-78-8
4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline
AB1004631
AC-1314
AC1L4LL4
AKOS005145766
CHEBI:49603
CHEMBL1201179
CHEMBL554
CID11557040
CID208908
D04024
D08108
DB01259
DB02584
EN002712
FMM
GSK 572016
GSK572016
GW 572016
GW 572016X
GW-2016
GW-572016
GW-572016F
GW2016
GW572016
HMS2089H10
I01-1247
 
Kinome_3684
Kinome_3685
LAPATINIB DITOSYLATE MONOHYDRATE
LS-187029
LS-187771
Lapatinib
Lapatinib (INN)
Lapatinib Ditosylate
Lapatinib [INN]
Lapatinib ditosylate
Lapatinib ditosylate (USAN)
Lapatinib tosilate hydrate
Lapatinib tosilate hydrate (JAN)
Lapatinib, Tykerb, GW572016
N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine
N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine
N-(3-chloro-4-((3-Fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine
N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE
N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine
NCGC00167507-01
NSC745750
TL80090051
Tycerb
Tykerb
Tykerb (TN)
Tyverb
UNII-0VUA21238F
lapatinib
lapatinib ditosylate
nchembio866-comp20
19Protein Kinase InhibitorsEarly Phase 13612
20Insulin, Globin Zinc4523
21insulin4524
22Hypoglycemic Agents5733

Interventional clinical trials:

idNameStatusNCT IDPhase
1Exploratory Study on the Use of Pregabalin for the Treatment of Taxol Related Arthralgia-MyalgiaUnknown statusNCT02024568Phase 2
2A Phase I/II Study of BGT226 in Adult Patients With Advanced Solid Malignancies Including Patients With Advanced Breast CancerCompletedNCT00600275Phase 1, Phase 2
3AZD2281 Plus Carboplatin to Treat Breast and Ovarian CancerActive, not recruitingNCT01445418Phase 1
4Metabolic Syndrome as Modifiable Risk Factor for Breast CancerUnknown statusNCT01172886
5Concentration and Activity of Lapatinib in Vestibular SchwannomasUnknown statusNCT00863122Early Phase 1
6Insulin Resistance and Breast CancerCompletedNCT00304941
7Targeted Next-generation Sequencing Panel for Identification of Germline Mutations in Early Onset Cancers With Sporadic or Hereditary PresentationRecruitingNCT02664389
8Feasibility of Lifestyle Intervention in BRCA1/2 Mutation CarriersActive, not recruitingNCT02087592

Search NIH Clinical Center for Sporadic Breast Cancer

Genetic Tests for Sporadic Breast Cancer

About this section

Anatomical Context for Sporadic Breast Cancer

About this section

MalaCards organs/tissues related to Sporadic Breast Cancer:

36
Breast, Endothelial

Publications for Sporadic Breast Cancer

About this section

Articles related to Sporadic Breast Cancer:

(show top 50)    (show all 274)
idTitleAuthorsYear
1
Simultaneous ATM/BRCA1/RAD51 expression variations associated with prognostic factors in Iranian sporadic breast cancer patients. (28058614)
2017
2
Homozygous T172T and Heterozygous G135C Variants of Homologous Recombination Repairing Protein RAD51 are Related to Sporadic Breast Cancer Susceptibility. (26650628)
2016
3
Association between genetic variants of EGF-containing fibulin-like extracellular matrix protein1 gene and sporadic breast cancer in a Chinese Han population. (27048115)
2016
4
Twenty-one-gene recurrence score assay in BRCA-associated versus sporadic breast cancers: Differences based on germline mutation status. (26859126)
2016
5
Differential Cytotoxicity, Cellular Uptake, Apoptosis and Inhibition of BRCA1 Expression of BRCA1-Defective and Sporadic Breast Cancer Cells Induced by an Anticancer Ruthenium(II)-Arene Compound, RAPTA-EA1. (27039925)
2016
6
Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients. (26205471)
2016
7
RECQL4 helicase has oncogenic potential in sporadic breast cancers. (26690729)
2016
8
Contralateral risk reducing mastectomy in patients with sporadic breast cancer. Benefits and hazards. (27189832)
2016
9
A study on promoter methylation of PTEN in sporadic breast cancer patients from North India. (26754093)
2016
10
A Genome-Wide Association Study to Identify Potential Germline Copy Number Variants for Sporadic Breast Cancer Susceptibility. (27668787)
2016
11
Promoter Methylation Status of Breast Cancer Susceptibility Gene 1 and 17 Beta Hydroxysteroid Dehydrogenase Type 1 Gene in Sporadic Breast Cancer Patients. (27413552)
2016
12
Relationship of immunohistochemistry, copy number aberrations and epigenetic disorders with BRCAness pattern in hereditary and sporadic breast cancer. (26723934)
2016
13
Signatures of post-zygotic structural genetic aberrations in the cells of histologically normal breast tissue that can predispose to sporadic breast cancer. (26430163)
2015
14
Decreased Expression of BRCA2 Accelerates Sporadic Breast Cancer Progression. (27065665)
2015
15
Association of CYP1A1 A4889G and T6235C polymorphisms with the risk of sporadic breast cancer in Brazilian women. (26598080)
2015
16
Association of the microRNA-Single Nucleotide Polymorphism rs2910164 in miR146a with sporadic breast cancer susceptibility: A case control study. (26476291)
2015
17
ATM gene mutations in sporadic breast cancer patients from Brazil. (25625042)
2015
18
Mutational analysis of BRCA1/2 gene and pathologic characteristics from Kazakh population with sporadic breast cancer in northwestern China. (26535628)
2015
19
Personalised pathway analysis reveals association between DNA repair pathway dysregulation and chromosomal instability in sporadic breast cancer. (26456802)
2015
20
First description of a sporadic breast cancer in a woman with BRCA1 germline mutation. (26426992)
2015
21
Promoter methylation and expression changes of BRCA1 in cancerous tissues of patients with sporadic breast cancer. (25789047)
2015
22
Association of BRCA1 promoter methylation with sporadic breast cancers: Evidence from 40 studies. (26643130)
2015
23
A novel BRCA2 in frame deletion in a Tunisian woman with early onset sporadic breast cancer. (26320393)
2015
24
DNA repair genes XRCC1 and ERCC1 polymorphisms and the risk of sporadic breast cancer in Han women in the Gansu Province of China. (25961110)
2015
25
Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer. (26526077)
2015
26
Assessing Heavy Metal and PCB Exposure from Tap Water by Measuring Levels in Plasma from Sporadic Breast Cancer Patients, a Pilot Study. (26690196)
2015
27
The CHEK2 1100delC allelic variant is not present in familial and sporadic breast cancer cases from Moroccan population. (25674498)
2015
28
Expression of base excision repair key factors and miR17 in familial and sporadic breast cancer. (24556691)
2014
29
DNA methyltransferase 1/3a overexpression in sporadic breast cancer is associated with reduced expression of estrogen receptor-alpha/breast cancer susceptibility gene 1 and poor prognosis. (24464625)
2014
30
Combined microRNA and ER expression: a new classifier for familial and sporadic breast cancer patients. (25406994)
2014
31
BRCA1 gene exon 11 mutations in Uighur and Han women with early-onset sporadic breast cancer in the northwest region of China. (24969878)
2014
32
A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. (25067956)
2014
33
Association of promoter methylation of ERI+ and ERI^ with sporadic breast cancer--a study from North India. (24833090)
2014
34
Association of +405C>G and +936C>T polymorphisms of the vascular endothelial growth factor gene with sporadic breast cancer in North Indians. (24528036)
2014
35
Association of TNF-I+, TNFRSF1A and TNFRSF1B gene polymorphisms with the risk of sporadic breast cancer in northeast Chinese Han women. (25010932)
2014
36
Limited family structure and triple-negative breast cancer (TNBC) subtype as predictors of BRCA mutations in a genetic counseling cohort of early-onset sporadic breast cancers. (25342642)
2014
37
Clinicopathological significance of ATM-Chk2 expression in sporadic breast cancers: a comprehensive analysis in large cohorts. (25425972)
2014
38
The Study of DNA Methyltransferase-3B Promoter Variant Genotype among Iranian Sporadic Breast Cancer Patients. (24850984)
2014
39
The promoter methylation status and mRNA expression levels of CTCF and SIRT6 in sporadic breast cancer. (24842653)
2014
40
MYC overexpression and poor prognosis in sporadic breast cancer with BRCA1 deficiency. (23860775)
2013
41
Imaging features of sporadic breast cancer in women under 40 years old: 97 cases. (23918218)
2013
42
Potential clinical significance of ERI^ ON promoter methylation in sporadic breast cancer. (23794253)
2013
43
Contralateral risk-reducing mastectomy in sporadic breast cancer. (23725708)
2013
44
Association of BRCA1 promoter methylation with rs11655505 (c.2265C>T) variants and decreased gene expression in sporadic breast cancer. (23263908)
2013
45
Genetic variant rs16430 6bpa88>a880bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-hispanic white women aged a8o55a88years. (24166930)
2013
46
HVEM gene polymorphisms are associated with sporadic breast cancer in Chinese women. (23976978)
2013
47
Copy number variation in ACHE/EPHB4 (7q22) and in BCHE/MME (3q26) genes in sporadic breast cancer. (23063927)
2013
48
Loss of WIF-1 and Wnt5a expression is related to aggressiveness of sporadic breast cancer in Tunisian patients. (23417837)
2013
49
The TP53 gene polymorphisms and survival of sporadic breast cancer patients. (21365326)
2012
50
Higher cytoplasmic and nuclear poly(ADP-ribose) polymerase expression in familial than in sporadic breast cancer. (22968923)
2012

Variations for Sporadic Breast Cancer

About this section

Expression for genes affiliated with Sporadic Breast Cancer

About this section
Search GEO for disease gene expression data for Sporadic Breast Cancer.

Pathways for genes affiliated with Sporadic Breast Cancer

About this section

Pathways related to Sporadic Breast Cancer according to GeneCards Suite gene sharing:

(show all 38)
idSuper pathwaysScoreTop Affiliating Genes
19.8CHEK2, TP53
2
Show member pathways
9.7BRCA1, BRCA2, RAD51
39.7ATM, BRCA1, TP53
49.7ATM, BRCA1, TP53
5
Show member pathways
9.6ATM, CHEK2, TP53
6
Show member pathways
9.6ATM, CHEK2, TP53
7
Show member pathways
9.6ATM, CHEK2, TP53
89.5ATM, BRCA1, XRCC1
9
Show member pathways
9.5ATM, BRCA1, BRCA2, RAD51
109.5ERBB2, PTEN, TP53
11
Show member pathways
9.4BRCA1, CHEK2, ESR1, PGR
129.4ESR1, ESR2
13
Show member pathways
9.4BRCA2, ERBB2, RAD51, TP53
14
Show member pathways
9.3ATM, CHEK2, ERBB2, TP53
15
Show member pathways
9.2ESR1, ESR2, PGR
169.2BRCA2, CHEK2, ESR1, XRCC1
179.2ATM, ESR2, PGR
18
Show member pathways
9.1ATM, CHEK2, PTEN, TP53
19
Show member pathways
9.1ATM, BARD1, BRCA1, BRCA2, RAD51
20
Show member pathways
9.0ATM, BRCA1, CHEK2, RAD51, TP53
219.0ATM, BRCA1, ERBB2, PTEN, TP53
229.0ATM, BARD1, BRCA1, RAD51, TP53
23
Show member pathways
9.0ATM, BARD1, BRCA1, CHEK2, TP53
249.0ATM, BARD1, BRCA1, CHEK2, TP53
25
Show member pathways
9.0ATM, BARD1, BRCA1, CHEK2, TP53
268.9BRCA2, ERBB2, PTEN, RAD51, TP53
27
Show member pathways
8.9ATM, BRCA1, CHEK2, PTEN, TP53
28
Show member pathways
8.8ATM, BRCA1, BRCA2, ERBB2, PTEN, TP53
298.5ATM, BRCA1, CHEK2, RAD51, TP53, XRCC1
30
Show member pathways
8.5ATM, BARD1, BRCA1, CHEK2, PTEN, TP53
31
Show member pathways
8.4ATM, BARD1, BRCA1, BRCA2, CHEK2, RAD51
32
Show member pathways
8.4ATM, BARD1, BRCA1, BRCA2, CHEK2, RAD51
33
Show member pathways
8.4ATM, BARD1, BRCA1, BRCA2, CHEK2, RAD51
34
Show member pathways
7.9ATM, BARD1, BRCA1, BRCA2, CHEK2, RAD51
357.7ATM, BARD1, BRCA1, BRCA2, CHEK2, ESR1
36
Show member pathways
7.2ATM, BARD1, BRCA1, CHEK2, ESR1, ESR2
377.0ATM, BRCA1, BRCA2, CHEK2, ERBB2, ESR1
38
Show member pathways
6.8ATM, BARD1, BRCA1, BRCA2, CHEK2, ESR1

GO Terms for genes affiliated with Sporadic Breast Cancer

About this section

Cellular components related to Sporadic Breast Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1BRCA1-A complexGO:007053110.6BARD1, BRCA1
2BRCA1-BARD1 complexGO:003143610.6BARD1, BRCA1
3PML bodyGO:00166059.1CHEK2, PTEN, RAD51, TP53
4nucleoplasmGO:00056546.4ATM, BARD1, BRCA1, BRCA2, CHEK2, EMSY

Biological processes related to Sporadic Breast Cancer according to GeneCards Suite gene sharing:

(show all 31)
idNameGO IDScoreTop Affiliating Genes
1chordate embryonic developmentGO:004300910.8BRCA1, BRCA2
2chromosome breakageGO:003105210.8BRCA1, BRCA2
3determination of adult lifespanGO:000834010.7ATM, TP53
4mitotic recombination-dependent replication fork processingGO:199042610.7BRCA2, RAD51
5DNA damage induced protein phosphorylationGO:000697510.6ATM, CHEK2
6protein K6-linked ubiquitinationGO:008502010.5BARD1, BRCA1
7DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorGO:000697810.5BRCA1, BRCA2, TP53
8double-strand break repairGO:000630210.4BRCA1, BRCA2, CHEK2
9DNA double-strand break processingGO:000072910.4ATM, BARD1, BRCA1
10double-strand break repair via nonhomologous end joiningGO:000630310.3ATM, BARD1, BRCA1
11DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestGO:000697710.3ATM, CHEK2, TP53
12replicative senescenceGO:009039910.2ATM, CHEK2, TP53
13intrinsic apoptotic signaling pathway in response to DNA damageGO:000863010.2ATM, BRCA1, BRCA2, CHEK2
14response to gamma radiationGO:001033210.2BRCA2, CHEK2, TP53
15regulation of apoptotic processGO:004298110.1ATM, BRCA1, ESR1, TP53
16response to X-rayGO:001016510.1BRCA2, RAD51, TP53
17response to nutrientGO:000758410.1BRCA1, BRCA2, PTEN
18response to estradiolGO:003235510.0BRCA1, BRCA2, ESR1, PTEN
19DNA repairGO:00062819.8ATM, EMSY, RAD51, XRCC1
20Sertoli cell developmentGO:00600099.8ESR1, ESR2
21Sertoli cell proliferationGO:00600119.8ESR1, ESR2
22DNA synthesis involved in DNA repairGO:00007319.8ATM, BARD1, BRCA1, BRCA2, RAD51
23response to estrogenGO:00436279.8BRCA1, ESR1, ESR2
24cellular response to drugGO:00356909.8CHEK2, ESR2, TP53
25double-strand break repair via homologous recombinationGO:00007249.7ATM, BRCA1, BRCA2, RAD51, XRCC1
26positive regulation of sequence-specific DNA binding transcription factor activityGO:00510919.7ESR1, ESR2, PTEN
27regulation of signal transduction by p53 class mediatorGO:19017969.6ATM, BARD1, BRCA1, CHEK2, TP53
28strand displacementGO:00007329.1ATM, BARD1, BRCA1, BRCA2, RAD51
29positive regulation of transcription, DNA-templatedGO:00458939.0BRCA1, BRCA2, CHEK2, ESR1, ESR2, TP53
30positive regulation of apoptotic processGO:00430659.0ATM, BARD1, ESR2, PTEN, TP53
31cellular response to DNA damage stimulusGO:00069748.6ATM, BARD1, BRCA1, BRCA2, CHEK2, RAD51

Molecular functions related to Sporadic Breast Cancer according to GeneCards Suite gene sharing:

(show all 9)
idNameGO IDScoreTop Affiliating Genes
1damaged DNA bindingGO:000368410.2BRCA1, TP53, XRCC1
2estrogen receptor activityGO:003028410.1ESR1, ESR2
3estrogen response element bindingGO:003405610.1ESR1, ESR2
4RNA polymerase II transcription factor activity, estrogen-activated sequence-specific DNA bindingGO:00380529.9ESR1, ESR2
5core promoter sequence-specific DNA bindingGO:00010469.8ESR1, ESR2, TP53
6steroid bindingGO:00054969.7ESR1, ESR2, PGR
7steroid hormone receptor activityGO:00037079.2ESR1, ESR2, PGR
8identical protein bindingGO:00428029.1CHEK2, ERBB2, ESR1, PTEN, RAD51, TP53
9enzyme bindingGO:00198997.8BRCA1, ESR1, ESR2, GSTM1, PGR, PTEN

Sources for Sporadic Breast Cancer

About this section
2CDC
6CNVD
10DGIdb
15ExPASy
16FDA
17FMA
27GTR
28HGMD
29HMDB
30ICD10
31ICD10 via Orphanet
32ICD9CM
33IUPHAR
34KEGG
37MedGen
39MeSH
40MESH via Orphanet
41MGI
44NCI
45NCIt
46NDF-RT
49NINDS
50Novoseek
52OMIM
53OMIM via Orphanet
57PubMed
58QIAGEN
63SNOMED-CT via Orphanet
67Tumor Gene Family of Databases
68UMLS
69UMLS via Orphanet